Venture Capital Investors

Third Rock Ventures

Third Rock Ventures makes VC investments in techn-focused companies.

Venture Investor Overview

Venture Investor
Third Rock Ventures
Status
Active
Investor Type
Venture Capital
Activity Level
159 transactions
Funds Raised
At least $2.7 billion
Industry Focus
Biopharmaceutical
Healthcare Services
Life Sciences

Contact Information

Contact
Alexis Borisy
Title
Partner
Mailing Address
29 Newbury Street 3rd Floor
Boston, MA 02116
USA
Phone
(617) 585-2000
Website
www.thirdrockventures.com
Email Address
Not Recorded

Background Information

Overview
At Third Rock Ventures, our passion is the creation of meaningful life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. We work collaboratively with entrepreneurs to focus on creating value from technologies that have the potential for delivering multiple product opportunities.
Profile
Third Rock Ventures LinkedIn Company Profile
Social Media
Third Rock Ventures Company Twitter Account
Company News
Third Rock Ventures News
Facebook
Third Rock Ventures on Facebook
YouTube
Third Rock Ventures on YouTube
Last Transaction
12/3/2024

Transaction History

Our records indicate that Third Rock Ventures invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Maze Therapeutics
12/3/2024
$115,000,000
Trace Neuroscience
11/12/2024
$101,000,000
Seaport Therapeutics
10/21/2024
$225,000,000
Candid Therapeutics
9/9/2024
$370,000,000
Marea Therapeutics
6/18/2024
$190,000,000
Asher Bio
4/17/2024
$55,000,000
Seaport Therapeutics
4/10/2024
$100,000,000
Clasp Therapeutics
3/20/2024
$150,000,000
ARTBIO
12/7/2023
$90,000,000
Rapport Therapeutics
8/23/2023
$150,000,000
Septerna
7/12/2023
$150,000,000
Flare Therapeutics
3/22/2023
$123,000,000
Rapport Therapeutics
3/7/2023
$100,000,000
CARGO Therapeutics
3/1/2023
$200,000,000
Casma Therapeutics
11/15/2022
$46,000,000
Terremoto Biosciences
5/25/2022
$75,000,000
Moma Therapeutics
5/10/2022
$150,000,000
Celsius Therapeutics
3/24/2022
Unknown
Septerna
2/3/2022
$100,000,000
Ambys Medicines
12/22/2021
$47,000,000
Cedilla Therapeutics
10/26/2021
$25,000,000
Asher Bio
9/2/2021
$108,000,000
Abata Therapeutics
6/24/2021
$95,000,000
Asher Bio
3/25/2021
$55,000,000
insitro
3/16/2021
$400,000,000
Decibel Therapeutics
11/10/2020
$82,000,000
Cedilla Therapeutics
10/14/2020
$57,600,000
Casma Therapeutics
9/11/2020
$50,000,000
insitro
5/27/2020
$143,000,000
Moma Therapeutics
4/16/2020
$86,000,000
Nurix Therapeutics
3/13/2020
$120,000,000
Element Science
3/4/2020
$145,600,000
Revolution Medicines
7/11/2019
$100,000,000
Thrive Earlier Detection
5/31/2019
$110,000,000
Maze Therapeutics
3/1/2019
$191,000,000
Ambys Medicines
8/10/2018
$140,000,000
Decibel Therapeutics
6/20/2018
$55,000,000
Celsius Therapeutics
5/16/2018
$65,000,000
Casma Therapeutics
5/4/2018
$58,500,000
Cedilla Therapeutics
4/25/2018
$56,200,000
Revolution Medicines
4/25/2018
$56,000,000
Constellation Pharmaceuticals
4/10/2018
$100,000,000
Rheos Medicines
3/23/2018
$60,000,000
Relay Therapeutics
12/15/2017
$63,000,000
PanOptica
10/10/2017
$11,000,000
Magenta Therapeutics
5/3/2017
$50,000,000
RHYTHM Health
2/18/2017
$41,000,000
Neon Therapeutics
1/6/2017
$70,000,000
Revolution Medicines
12/22/2016
$25,000,000
Goldfinch Bio
12/15/2016
$55,000,000
Magenta Therapeutics
11/17/2016
$48,500,000
Relay Therapeutics
9/15/2016
$57,000,000
Fulcrum Therapeutics
7/21/2016
$55,000,000
Neon Therapeutics
3/31/2016
$6,727,000
Decibel Therapeutics
3/31/2016
$8,000,000
PanOptica
3/31/2016
$11,257,000
Igenica
3/31/2016
$2,250,000
Pliant Therapeutics
2/19/2016
$45,000,000
RHYTHM Health
12/31/2015
$15,000,000
Constellation Pharmaceuticals
12/10/2015
$55,000,000
Decibel Therapeutics
10/16/2015
$52,000,000
Neon Therapeutics
10/2/2015
$55,000,000
Pliant Components
9/30/2015
$6,500,000
Corvia Medical
9/30/2015
$16,950,000
Revolution Medicines
2/5/2015
$45,000,000
CytomX Therapeutics
1/6/2015
$20,000,000
Blueprint Medicines
11/14/2014
$50,000,000
Allena Pharmaceuticals
11/14/2014
$25,000,000
DC Devices
7/1/2014
$34,000,000
Nurix Therapeutics
5/22/2014
$25,100,000
Kala Pharmaceuticals
4/23/2014
$22,500,000
PanOptica
4/15/2014
$45,000,000
Element Science
3/31/2014
$12,500,100
NinePoint Medical
3/18/2014
$34,558,476
Marina Biotech
3/13/2014
$38,000,000
Voyager Therapeutics
2/13/2014
$45,000,000
Igenica
1/28/2014
$14,000,000
Blueprint Medicines
1/7/2014
$25,000,000
Editas Medicine
11/26/2013
$43,000,000
Sage Therapeutics
10/16/2013
$20,000,000
Rhythm Pharmaceuticals
9/30/2013
$11,000,000
Jounce Therapeutics
9/30/2013
Unknown
Global Blood Therapeutics
9/30/2013
Unknown
Afferent Pharmaceuticals
9/30/2013
$3,000,000
Kala Pharmaceuticals
9/30/2013
$2,499,000
Blueprint Medicines
9/30/2013
Unknown
Edimer Pharmaceuticals
7/30/2013
$18,000,000
Alcresta Therapeutics
7/22/2013
$10,000,000
Igenica
6/30/2013
$13,030,100
TARIS Biomedical
4/2/2013
$12,500,000
Kala Pharmaceuticals
3/1/2013
$11,500,000
Jounce Therapeutics
2/14/2013
$47,000,000
Igenica
12/31/2012
$10,250,000
Zafgen
12/4/2012
$21,000,000
Cibiem
10/18/2012
$10,000,000
Alcresta Therapeutics
9/30/2012
$5,000,000
MyoKardia
9/21/2012
$38,000,000
Foundation Medicine
9/21/2012
$56,000,000
CytomX Therapeutics
7/31/2012
$31,000,000
Allena Pharmaceuticals
6/30/2012
$7,500,000
DC Devices
6/30/2012
$500,000
Lotus Tissue Repair
6/30/2012
$5,000,000
Sage Therapeutics
6/30/2012
$4,000,000
Foundation Medicine
6/30/2012
$6,199,000
Global Blood Therapeutics
6/15/2012
$40,700,000
Igenica
6/12/2012
$33,000,000
Rhythm Pharmaceuticals
6/4/2012
$25,000,000
Nurix Therapeutics
5/17/2012
$3,100,000
Sesen Bio
5/8/2012
$20,000,000
Alcresta Therapeutics
4/18/2012
$10,000,000
Afferent Pharmaceuticals
3/31/2012
$5,000,000
PanOptica
3/31/2012
$6,047,000
Ember Therapeutics
3/31/2012
$7,000,000
Edimer Pharmaceuticals
3/31/2012
$5,682,000
Blueprint Medicines
3/31/2012
$5,999,000
NinePoint Medical
3/31/2012
$6,000,000
Zafgen
3/31/2012
$3,488,000
Kala Pharmaceuticals
3/14/2012
$6,200,000
Afferent Pharmaceuticals
12/31/2011
$2,000,000
Coridea
12/31/2011
$2,000,000
Zafgen
12/31/2011
$1,000,000
Ember Therapeutics
12/15/2011
$34,000,000
Allena Pharmaceuticals
11/17/2011
$15,000,000
Agios Pharmaceuticals
11/17/2011
$78,000,000
Topica Pharmaceuticals
10/18/2011
$27,000,000
Sage Therapeutics
10/18/2011
$35,000,000
Zafgen
7/7/2011
$33,000,000
Lotus Tissue Repair
6/30/2011
$26,000,000
Afferent Pharmaceuticals
6/30/2011
$2,000,000
Constellation Pharmaceuticals
6/6/2011
$15,000,000
Seventh Sense Biosystems
5/11/2011
$4,500,000
bluebird bio
4/20/2011
$30,000,000
TARIS Biomedical
4/13/2011
$18,300,000
Blueprint Medicines
4/11/2011
$40,000,000
Foundation Medicine
3/31/2011
$6,000,000
NinePoint Medical
3/31/2011
$10,000,000
Zafgen
3/31/2011
$2,025,000
Sesen Bio
3/31/2011
$11,000,000
PanOptica
1/4/2011
$30,000,000
NinePoint Medical
10/14/2010
$33,000,000
CytomX Therapeutics
9/23/2010
$30,000,000
Rhythm Pharmaceuticals
9/8/2010
$19,000,000
Afferent Pharmaceuticals
6/30/2010
$2,826,400
Aleksey
6/2/2010
$12,000,000
Constellation Pharmaceuticals
6/2/2010
$22,000,000
Foundation Medicine
4/14/2010
Unknown
bluebird bio
3/12/2010
$35,000,000
Zafgen
3/1/2010
$8,100,000
Sesen Bio
2/17/2010
$35,000,000
Alnara Pharmaceuticals
1/28/2010
$35,000,000
Kala Pharmaceuticals
12/31/2009
$657,000
Afferent Pharmaceuticals
12/16/2009
$23,000,000
Agios Pharmaceuticals
9/30/2009
$18,000,000
Constellation Pharmaceuticals
8/13/2009
$17,200,000
Edimer Pharmaceuticals
6/30/2009
Unknown
Seventh Sense Biosystems
12/16/2008
$4,180,000
Alnara Pharmaceuticals
10/30/2008
$20,000,000
Agios Pharmaceuticals
7/7/2008
$33,000,000
Constellation Pharmaceuticals
4/29/2008
$32,000,000

 

Investor Contacts

Title
Name
Email & Social
Principal
Brian Albrecht
  Brian Albrecht LinkedIn Profile  Brian Albrecht Twitter Account  Brian Albrecht News  Brian Albrecht on Facebook
Partner
Alexis Borisy
  Alexis Borisy LinkedIn Profile  Alexis Borisy Twitter Account  Alexis Borisy News  Alexis Borisy on Facebook
Partner
Abbie Celniker
  Abbie Celniker LinkedIn Profile  Abbie Celniker Twitter Account  Abbie Celniker News  Abbie Celniker on Facebook
Partner
Neil Exter
  Neil Exter LinkedIn Profile  Neil Exter Twitter Account  Neil Exter News  Neil Exter on Facebook
Partner
Kevin Gillis
  Kevin Gillis LinkedIn Profile  Kevin Gillis Twitter Account  Kevin Gillis News  Kevin Gillis on Facebook
Partner
Charles Homcy
  Charles Homcy LinkedIn Profile  Charles Homcy Twitter Account  Charles Homcy News  Charles Homcy on Facebook
Partner
Reid Huber
  Reid Huber LinkedIn Profile  Reid Huber Twitter Account  Reid Huber News  Reid Huber on Facebook
Partner
Christopher Langauer
  Christopher Langauer LinkedIn Profile  Christopher Langauer Twitter Account  Christopher Langauer News  Christopher Langauer on Facebook
Partner
Sarah Larson
  Sarah Larson LinkedIn Profile  Sarah Larson Twitter Account  Sarah Larson News  Sarah Larson on Facebook
Partner
Mark Levin
  Mark Levin LinkedIn Profile  Mark Levin Twitter Account  Mark Levin News  Mark Levin on Facebook
Partner
Craig Muir
  Craig Muir LinkedIn Profile  Craig Muir Twitter Account  Craig Muir News  Craig Muir on Facebook
Partner
Cary Pfeffer
  Cary Pfeffer LinkedIn Profile  Cary Pfeffer Twitter Account  Cary Pfeffer News  Cary Pfeffer on Facebook
Partner
Kevin Starr
  Kevin Starr LinkedIn Profile  Kevin Starr Twitter Account  Kevin Starr News  Kevin Starr on Facebook
Partner
Robert Tepper
  Robert Tepper LinkedIn Profile  Robert Tepper Twitter Account  Robert Tepper News  Robert Tepper on Facebook
Partner
Jeffrey Tong
  Jeffrey Tong LinkedIn Profile  Jeffrey Tong Twitter Account  Jeffrey Tong News  Jeffrey Tong on Facebook

 

Funds

Our database includes the following fund closing(s) for Third Rock Ventures. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Third Rock Ventures V
6/7/2019
$750,000,000
Third Rock Ventures IV
10/31/2016
$616,000,000
Third Rock Ventures III
3/25/2013
$516,000,000
Third Rock Ventures II
9/13/2010
$426,000,000
Third Rock Ventures I
3/31/2007
$378,000,000

 

Portfolio Companies

Third Rock Ventures has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Abata Therapeutics
Afferent Pharmaceuticals
Agios Pharmaceuticals
Alcresta Therapeutics
Aleksey
Allena Pharmaceuticals
Alnara Pharmaceuticals
Ambys Medicines
ARTBIO
Asher Bio
bluebird bio
Blueprint Medicines
Candid Therapeutics
CARGO Therapeutics
Casma Therapeutics
Cedilla Therapeutics
Celsius Therapeutics
Cibiem
Clasp Therapeutics
Constellation Pharmaceuticals
Coridea
Corvia Medical
CytomX Therapeutics
DC Devices
Decibel Therapeutics
Edimer Pharmaceuticals
Editas Medicine
Element Science
Ember Therapeutics
Flare Therapeutics
Foundation Medicine
Fulcrum Therapeutics
Global Blood Therapeutics
Goldfinch Bio
Igenica
insitro
Jounce Therapeutics
Kala Pharmaceuticals
Lotus Tissue Repair
Magenta Therapeutics
Marea Therapeutics
Marina Biotech
Maze Therapeutics
Moma Therapeutics
MyoKardia
Neon Therapeutics
NinePoint Medical
Nurix Therapeutics
PanOptica
Pliant Components
Pliant Therapeutics
Rapport Therapeutics
Relay Therapeutics
Revolution Medicines
Rheos Medicines
RHYTHM Health
Rhythm Pharmaceuticals
Sage Therapeutics
Seaport Therapeutics
Septerna
Sesen Bio
Seventh Sense Biosystems
TARIS Biomedical
Terremoto Biosciences
Thrive Earlier Detection
Topica Pharmaceuticals
Trace Neuroscience
Voyager Therapeutics
Zafgen

 

 

 

 

Browse more venture capital investors:

Third Prime Capital | Third Security

 

Share this article

 

About Our Venture Capital Investors Database

This VC firm profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.